FWB:EVK

Track all markets on TradingView - Graphs are not on time
Evonik Industries AG confirmed it met its 2025 profit guidance and reaffirmed its earnings outlook for 2026.

The company reported adjusted EBITDA of €1.87 billion for 2025, in line with its forecast of around €1.9 billion. Sales declined 7% to €14.1 billion, while net income increased to €265 million. Free cash flow reached €695 million, supporting a cash conversion rate of 37%.

Evonik expects adjusted EBITDA between €1.7 billion and €2.0 billion in 2026 and proposed a dividend of €1.00 per share for 2025.
💬 🔗
Author
Global Finance News 03-04-26
Evonik announced a new, more flexible dividend policy while confirming it met its earnings guidance for 2025. Starting with the 2026 financial year, Evonik will target an annual shareholder distribution of 40–60% of adjusted net income, replacing the previous fixed approach. As a transition, the company plans to pay a dividend of €1.00 per share for 2025, down from €1.17 previously, implying a dividend yield of about 7%.

Evonik reported adjusted EBITDA of €1.874 billion for 2025, in line with guidance, despite sales declining around 7% year on year to €14.1 billion. Strong cash generation supported a free cash flow of €695 million and a cash conversion rate at the top of the target range. Net income rose to €265 million.

For 2026, Evonik expects adjusted EBITDA between €1.7 and €2.0 billion, citing a challenging economic environment. Management said the new dividend policy aims to balance shareholder returns with financial flexibility, investment capacity, and further deleveraging.
💬 🔗
Author
European Investor 02-08-26
Evonik reports weak third quarter amid sluggish demand

Evonik Industries AG announced a 22% year-on-year decline in third-quarter adjusted EBITDA to €448 million, in line with prior guidance. Revenue dropped 12% to €3.39 billion, reflecting lower sales volumes, the sale of the superabsorbents business in 2024, and unfavorable currency movements. The adjusted EBITDA margin fell to 13.2% from 15.1% last year.

CEO Christian Kullmann said the expected September recovery “failed to materialize,” though he emphasized that long-term strategic goals remain intact. CFO Claus Rettig noted that despite current headwinds, adjusted full-year targets remain achievable, with EBITDA guidance reaffirmed at around €1.9 billion for 2025. Free cash flow for the quarter was €300 million, supported by disciplined cost and investment control.

Evonik’s restructuring program, **Tailor Made**, continues to progress, with 90% of business lines set to be reorganized by year-end. The company highlighted efficiency gains from streamlined management and reduced personnel costs.

By segment, **Advanced Technologies** revenue fell 6% to €1.45 billion and EBITDA dropped 32% to €202 million as planned maintenance and weak demand weighed on results. **Custom Solutions** revenue declined 9% to €1.34 billion, while EBITDA decreased 25% to €215 million due to lower volumes, particularly in additives for polyurethane foams and coatings.

For full-year 2025, Evonik expects continued weak demand but anticipates free cash flow remaining “attractive.” Capital expenditure will total about €750 million, and return on capital employed is projected to come in slightly below the 2024 level of 7.1%.
💬 🔗
Author
The Investor 11-05-25